Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Kyowa Kirin to Acquire ProStrakan for ￡292 Mil.
February 28, 2011
- Light Ahead for Japanese Bioventures: Mr Yamazaki of IRI
February 28, 2011
- Aloxi Gains Top Share in Antiemetic Market in Just 8 Months: Otsuka
February 28, 2011
- Daiichi Sankyo Acquires US Packaging, Manufacturing Facility
February 28, 2011
- Takeda Ties Up with Covance, Quintiles to Accelerate Development
February 28, 2011
- Sanofi-aventis to Acquire Genzyme for US$20.1 Bil.
February 28, 2011
- FUJIFILM to Develop Comprehensive Healthcare Business
February 28, 2011
- Sales Up 9.1% in Japan: sanofi-aventis
February 28, 2011
- Need to Omit Clinical Trials Pointed Out to Encourage Manufacturing of Mo-99 in Japan
February 28, 2011
- MTPC Voluntarily Withdraws Its Membership from JPMA
February 28, 2011
- Edoxaban Recommended for Approval for VTE
February 28, 2011
- Takeda to Enhance Research Collaboration with Third Parties
February 28, 2011
- Escitalopram to Prop Up Business of Struggling Mochida
February 28, 2011
- Abilify Approved for Maintenance Adjuvant Therapy for Bipolar I Disorder in US
February 28, 2011
- GSK Starts Multinational PIII Study for DMD
February 28, 2011
- Pfizer to Stress Significance of Combining CCB, Statin in One Drug
February 28, 2011
- Increasing Number of Trials Conducted on Concurrent Use of Oral Hypoglycemic Agents
February 28, 2011
- Mylan Aims to Become Top-3 Generic Company in Japan in 5 Years
February 28, 2011
- Takeda to Voluntarily Recall Dasen
February 28, 2011
- Lixisenatide Not Inferior to Exenatide in PIII: sanofi-aventis
February 28, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…